Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions

Rika Yuliwulandari; Usa Chaikledkaew; Kinasih Prayuni; Hilyatuz Zahroh; Surakameth Mahasirimongkol; Saowalak Turongkaravee; Jiraphun Jittikoon; Sukanya Wattanapokayakit; George P. Patrinos

doi:10.1016/B978-0-12-813382-8.00003-3

Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions

Rika Yuliwulandari
, Usa Chaikledkaew
, Kinasih Prayuni
, Hilyatuz Zahroh
, Surakameth Mahasirimongkol
, Saowalak Turongkaravee
, Jiraphun Jittikoon
, Sukanya Wattanapokayakit
, George P. Patrinos

Faculty of Medicine, YARSI University
YARSI University
Ministry of Public Health
School of Health Sciences
College of Medicine and Health Sciences United Arab Emirates University
United Arab Emirates University

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Citation (Scopus)

Abstract

Adverse drug reactions (ADRs) can cause treatment interruptions as well as disability and sometimes death. Recent developments in genetics have shown that some ADRs could be avoided by using pharmacogenetic tests before treatment initiation. However, due to their novelty, many countries, especially in Asia, are yet to implement pre-emptive genetic screenings in clinical settings. Several studies have been published on the cost-effectiveness of genetics screening before treatment initiation. This chapter discusses the potential pharmacoeconomic implications of human leukocyte antigen (HLA) typing associated with some well-known and studied ADRs and the associated implementation into routine care.

Original language	English
Title of host publication	Economic Evaluation in Genomic and Precision Medicine
Publisher	Elsevier
Pages	71-86
Number of pages	16
ISBN (Electronic)	9780128133828
ISBN (Print)	9780128133941
DOIs	https://doi.org/10.1016/B978-0-12-813382-8.00003-3
Publication status	Published - 1 Jan 2023

Keywords

Abacavir
Adverse drug reactions (ADRs)
Allopurinol
Carbamazepine
HLA alleles
Pharmacoeconomics
Severe cutaneous adverse drug reactions SCARs

Access to Document

10.1016/B978-0-12-813382-8.00003-3

Cite this

Yuliwulandari, R., Chaikledkaew, U., Prayuni, K., Zahroh, H., Mahasirimongkol, S., Turongkaravee, S., Jittikoon, J., Wattanapokayakit, S., & Patrinos, G. P. (2023). Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions. In Economic Evaluation in Genomic and Precision Medicine (pp. 71-86). Elsevier. https://doi.org/10.1016/B978-0-12-813382-8.00003-3

@inbook{2cb13d86bfbc47b29c20fde4693b86d7,

title = "Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions",

abstract = "Adverse drug reactions (ADRs) can cause treatment interruptions as well as disability and sometimes death. Recent developments in genetics have shown that some ADRs could be avoided by using pharmacogenetic tests before treatment initiation. However, due to their novelty, many countries, especially in Asia, are yet to implement pre-emptive genetic screenings in clinical settings. Several studies have been published on the cost-effectiveness of genetics screening before treatment initiation. This chapter discusses the potential pharmacoeconomic implications of human leukocyte antigen (HLA) typing associated with some well-known and studied ADRs and the associated implementation into routine care.",

keywords = "Abacavir, Adverse drug reactions (ADRs), Allopurinol, Carbamazepine, HLA alleles, Pharmacoeconomics, Severe cutaneous adverse drug reactions SCARs",

author = "Rika Yuliwulandari and Usa Chaikledkaew and Kinasih Prayuni and Hilyatuz Zahroh and Surakameth Mahasirimongkol and Saowalak Turongkaravee and Jiraphun Jittikoon and Sukanya Wattanapokayakit and Patrinos, \{George P.\}",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-813382-8.00003-3",

language = "English",

isbn = "9780128133941",

pages = "71--86",

booktitle = "Economic Evaluation in Genomic and Precision Medicine",

publisher = "Elsevier",

}

Yuliwulandari, R, Chaikledkaew, U, Prayuni, K, Zahroh, H, Mahasirimongkol, S, Turongkaravee, S , Jittikoon, J, Wattanapokayakit, S & Patrinos, GP 2023, Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions. in Economic Evaluation in Genomic and Precision Medicine. Elsevier, pp. 71-86. https://doi.org/10.1016/B978-0-12-813382-8.00003-3

TY - CHAP

T1 - Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions

AU - Yuliwulandari, Rika

AU - Chaikledkaew, Usa

AU - Prayuni, Kinasih

AU - Zahroh, Hilyatuz

AU - Mahasirimongkol, Surakameth

AU - Turongkaravee, Saowalak

AU - Jittikoon, Jiraphun

AU - Wattanapokayakit, Sukanya

AU - Patrinos, George P.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Adverse drug reactions (ADRs) can cause treatment interruptions as well as disability and sometimes death. Recent developments in genetics have shown that some ADRs could be avoided by using pharmacogenetic tests before treatment initiation. However, due to their novelty, many countries, especially in Asia, are yet to implement pre-emptive genetic screenings in clinical settings. Several studies have been published on the cost-effectiveness of genetics screening before treatment initiation. This chapter discusses the potential pharmacoeconomic implications of human leukocyte antigen (HLA) typing associated with some well-known and studied ADRs and the associated implementation into routine care.

AB - Adverse drug reactions (ADRs) can cause treatment interruptions as well as disability and sometimes death. Recent developments in genetics have shown that some ADRs could be avoided by using pharmacogenetic tests before treatment initiation. However, due to their novelty, many countries, especially in Asia, are yet to implement pre-emptive genetic screenings in clinical settings. Several studies have been published on the cost-effectiveness of genetics screening before treatment initiation. This chapter discusses the potential pharmacoeconomic implications of human leukocyte antigen (HLA) typing associated with some well-known and studied ADRs and the associated implementation into routine care.

KW - Abacavir

KW - Adverse drug reactions (ADRs)

KW - Allopurinol

KW - Carbamazepine

KW - HLA alleles

KW - Pharmacoeconomics

KW - Severe cutaneous adverse drug reactions SCARs

UR - https://www.scopus.com/pages/publications/85160694959

U2 - 10.1016/B978-0-12-813382-8.00003-3

DO - 10.1016/B978-0-12-813382-8.00003-3

M3 - Chapter

AN - SCOPUS:85160694959

SN - 9780128133941

SP - 71

EP - 86

BT - Economic Evaluation in Genomic and Precision Medicine

PB - Elsevier

ER -

Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this